A real-world analysis of trametinib in combination with hydroxychloroquine or CDK4/6 inhibitor as third- or later-line therapy in metastatic pancreatic adenocarcinoma

A real-world analysis of trametinib in combination with hydroxychloroquine or CDK4/6 inhibitor as third- or later-line therapy in metastatic pancreatic adenocarcinoma

Abstract Background There are no standard third-line treatment options for metastatic pancreatic ductal adenocarcinoma (mPDAC). Trametinib in combination with hydroxychloroquine (HCQ) or CDK4/6 inhibitors for pancreatic adenocarcinoma showed promising efficacy in preclinical studies. However, the re...

Full description

Bibliographic Details
Main Authors: Hui Tang, Yuping Ge, Tingting You, Xiaoyuan Li, Yingyi Wang, Yuejuan Cheng, Chunmei Bai
Format: Article
Language:English
Published: BMC 2023-10-01
Series:BMC Cancer
Subjects:
Pancreatic cancer
Later-line therapy
MEK inhibitor
Autophagy
Real-life data
Online Access:https://doi.org/10.1186/s12885-023-11464-3

Internet

https://doi.org/10.1186/s12885-023-11464-3

Similar Items